235 related articles for article (PubMed ID: 32440811)
41. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
[TBL] [Abstract][Full Text] [Related]
42. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB; Brodrick P
Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808
[TBL] [Abstract][Full Text] [Related]
43. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
44. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
45. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
46. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
47. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
48. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
49. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.
Kuwano M; Sonoda K; Murakami Y; Watari K; Ono M
Pharmacol Ther; 2016 May; 161():97-110. PubMed ID: 27000770
[TBL] [Abstract][Full Text] [Related]
50. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
51. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
52. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
53. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
54. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
55. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
56. Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.
Shao Y; Zhong DS
Int J Clin Oncol; 2018 Apr; 23(2):235-242. PubMed ID: 29110101
[TBL] [Abstract][Full Text] [Related]
57. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
59. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.
Tomasello C; Baldessari C; Napolitano M; Orsi G; Grizzi G; Bertolini F; Barbieri F; Cascinu S
Crit Rev Oncol Hematol; 2018 Mar; 123():149-161. PubMed ID: 29482776
[TBL] [Abstract][Full Text] [Related]
60. MET and ALK as targets for the treatment of NSCLC.
Capelletti M; Gelsomino F; Tiseo M
Curr Pharm Des; 2014; 20(24):3914-32. PubMed ID: 24138716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]